Literature DB >> 11714042

Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998.

A C Fluit1, J Verhoef, F J Schmitz.   

Abstract

A total of 3,981 isolates from patients treated at intensive care units were collected in 25 European university hospitals during 1997 and 1998 as part of the SENTRY Antimicrobial Surveillance Program. Overall, the most important species isolated were Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, coagulase-negative staphylococci (CNS), Enterobacter spp., Haemophilus influenzae, Streptococcus pneumoniae, and Enterococcus faecalis. Thirty-nine percent of all Staphylococcus aureus isolates were resistant to oxacillin. All Staphylococcus aureus isolates were fully susceptible to linezolid and vancomycin. Moreover, all CNS isolates were susceptible to vancomycin and minocycline. All Enterococcus faecalis isolates were susceptible to vancomycin, and 99% of these isolates were also susceptible to ampicillin. The antimicrobial agents most effective against Pseudomonas aeruginosa isolates were amikacin, piperacillin/tazobactam, meropenem, and cefepime, with 87, 85, 84, and 83% of isolates being susceptible, respectively. Escherichia coli isolates were fully susceptible to carbapenems, and at least 99% of these isolates were susceptible to ceftriaxone, cefepime, and amikacin. The Enterobacter spp. were also highly susceptible to carbapenems, amikacin, and cefepime, with 99, 97, and 96% of isolates being susceptible, respectively. Haemophilus influenzae was susceptible to most of the antibiotics tested. Only 68% of the pneumococcal isolates were fully susceptible to penicillin, yet 100% were susceptible to a number of fluoroquinolones and vancomycin. There are still sufficient treatment options for patients infected with the most important bacterial species involved in infections in intensive care units. However, the situation for patients with Pseudomonas aeruginosa infections is critical.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714042     DOI: 10.1007/s100960100564

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  26 in total

1.  Molecular evolution of methicillin-resistant Staphylococcus aureus in the metropolitan area of Cologne, Germany, from 1984 to 1998.

Authors:  Hilmar Wisplinghoff; Birgitta Ewertz; Susanne Wisplinghoff; Danuta Stefanik; Georg Plum; Francoise Perdreau-Remington; Harald Seifert
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

2.  Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus.

Authors:  Kunyan Zhang; Jo-Ann McClure; Sameer Elsayed; Thomas Louie; John M Conly
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

Review 3.  Molecular epidemiology of clinically significant antibiotic resistance genes.

Authors:  P M Hawkey
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

4.  Molecular epidemiology of Pseudomonas aeruginosa colonization in a burn unit: persistence of a multidrug-resistant clone and a silver sulfadiazine-resistant clone.

Authors:  Jean-Paul Pirnay; Daniel De Vos; Christel Cochez; Florence Bilocq; Jean Pirson; Marc Struelens; Luc Duinslaeger; Pierre Cornelis; Martin Zizi; Alain Vanderkelen
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

5.  Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections.

Authors:  Marlieke E A de Kraker; Martin Wolkewitz; Peter G Davey; Walter Koller; Jutta Berger; Jan Nagler; Claudine Icket; Smilja Kalenic; Jasminka Horvatic; Harald Seifert; Achim J Kaasch; Olga Paniara; Athina Argyropoulou; Maria Bompola; Edmond Smyth; Mairead Skally; Annibale Raglio; Uga Dumpis; Agita Melbarde Kelmere; Michael Borg; Deborah Xuereb; Mihaela C Ghita; Michelle Noble; Jana Kolman; Stanko Grabljevec; David Turner; Louise Lansbury; Hajo Grundmann
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

6.  Significance of methicillin-teicoplanin resistant Staphylococcus haemolyticus in bloodstream infections in patients of the Semmelweis University hospitals in Hungary.

Authors:  K Kristóf; E Kocsis; D Szabó; S Kardos; V Cser; K Nagy; P Hermann; F Rozgonyi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-11       Impact factor: 3.267

Review 7.  From clinical microbiology to infection pathogenesis: how daring to be different works for Staphylococcus lugdunensis.

Authors:  Kristi L Frank; José Luis Del Pozo; Robin Patel
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

8.  The antimicrobial activity of lapachol and its thiosemicarbazone and semicarbazone derivatives.

Authors:  Marina Azevêdo Souza; Susana Johann; Luciana Alves Rodrigues dos Santos Lima; Fernanda Fraga Campos; Isolda Castro Mendes; Heloisa Beraldo; Elaine Maria de Souza-Fagundes; Patrícia Silva Cisalpino; Carlos Augusto Rosa; Tânia Maria de Almeida Alves; Nívea Pereira de Sá; Carlos Leomar Zani
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-05       Impact factor: 2.743

9.  Correlation between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a medical-surgical intensive care unit.

Authors:  Hatem Kallel; Fouzia Mahjoubi; Hassen Dammak; Mabrouk Bahloul; Chokri Ben Hamida; Hedi Chelly; Noureddine Rekik; Adnéne Hammami; Mounir Bouaziz
Journal:  Indian J Crit Care Med       Date:  2008-01

10.  Evolution in quantum leaps: multiple combinatorial transfers of HPI and other genetic modules in Enterobacteriaceae.

Authors:  Armand Paauw; Maurine A Leverstein-van Hall; Jan Verhoef; Ad C Fluit
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.